Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07826364) titled 'A Randomized, Double-Blind, Dose-Escalation, Placebo-Controlled Study of SHR-1179 Injection in Participants With Obesity' on Sept. 4.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
Condition:
Body Weight Management
Intervention:
Drug: SHR-1179
Placebo
Drug: SHR-1179
Placebo
Drug: SHR-1179
Placebo
Drug: SHR-1179
Placebo
Drug: SHR-1179
Recruitment Status: Not recruiting
Phase: Phase 1 ...